These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 8109301)

  • 1. External and implanted pumps for apomorphine infusion in parkinsonism.
    Pollak P; Benabid AL; Limousin P; Gervason CL; Jeanneau-Nicolle E
    Acta Neurochir Suppl (Wien); 1993; 58():48-52. PubMed ID: 8109301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC; Sambrook MA; Crossman AR
    Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ; Konitsiotis S; Chase TN
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous apomorphine in parkinsonian on-off oscillations.
    Stibe CM; Lees AJ; Kempster PA; Stern GM
    Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys.
    Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Brain Res; 1996 May; 719(1-2):129-37. PubMed ID: 8782872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebroventricular infusion of dopamine and its agonists in rodents and primates. An experimental approach to the treatment of Parkinson's disease.
    Garcia de Yebenes J; Fahn S; Mena MA; Pardo B; Casarejos MJ
    ASAIO Trans; 1988; 34(4):951-7. PubMed ID: 2905893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonists in Parkinson's disease: a look at apomorphine.
    Lees AJ
    Fundam Clin Pharmacol; 1993; 7(3-4):121-8. PubMed ID: 8500783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
    Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
    Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism.
    Filion M; Tremblay L; Bédard PJ
    Brain Res; 1991 Apr; 547(1):152-61. PubMed ID: 1677608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Ozawa M; Yamaguchi M; Mizuta E; Kuno S
    Jpn J Pharmacol; 1995 Feb; 67(2):117-24. PubMed ID: 7616686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys.
    Akai T; Yamaguchi M; Mizuta E; Kuno S
    Ann Neurol; 1993 May; 33(5):507-11. PubMed ID: 8098931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Yoshimura N; Mizuta E; Kuno S; Sasa M; Yoshida O
    Neuropharmacology; 1993 Apr; 32(4):315-21. PubMed ID: 8098860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K; Hagell P; Odin P
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
    Bibbiani F; Costantini LC; Patel R; Chase TN
    Exp Neurol; 2005 Mar; 192(1):73-8. PubMed ID: 15698620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?
    Muhiddin KA; Roche MT; Pearce VR
    Postgrad Med J; 1994 May; 70(823):344-6. PubMed ID: 8016004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Practical use of continuous apomorphine infusion via pump].
    Tönges L; Ceballos-Baumann A; Honig H; Storch A; Jost WH
    Fortschr Neurol Psychiatr; 2017 Sep; 85(9):516-535. PubMed ID: 28817841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.